Jan van Lunzen
Affiliation: University Medical Center Hamburg-Eppendorf
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen
Infectious Diseases Unit, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
Lancet Infect Dis 12:111-8. 2012..SPRING-1 is an ongoing study designed to select a dose for phase 3 assessment. We present data from preplanned primary and interim analyses...
- Gene therapy strategies: can we eradicate HIV?Jan van Lunzen
Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
Curr HIV/AIDS Rep 8:78-84. 2011..Indeed the intriguing finding that HIV seems to be eradicated in an individual case study after stem cell transplantation with a mutant coreceptor (CCR5 delta 32 deletion) underlines the proof of the concept...
- Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCGPhilip Hartjen
Infectious Diseases Unit, I, Department of Internal Medicine, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20251 Hamburg, Germany
AIDS Res Ther 9:2. 2012..However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted...
- Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfectionJulian Schulze zur Wiesch
Department of Medicin, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Clin Infect Dis 49:466-72. 2009..We present detailed clinical and immunological analysis of 3 individuals after concomitant infection with acute HCV and primary HIV...
- Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustionIlona Tóth
1 Section Infectious Diseases, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
J Leukoc Biol 94:551-61. 2013..These data indicate that down-regulation of CD73 on CD8(+) T cells correlates with immune activation and leads to functional deficits in HIV infection. ..
- Improved outcome with rituximab in patients with HIV-associated multicentric Castleman diseaseChristian Hoffmann
Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany
Blood 118:3499-503. 2011....
- Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasisChristian Hoffmann
University Medical Centre Hamburg Eppendorf, Hamburg, Germany
Br J Haematol 136:641-8. 2007..The clearance kinetics of the transfused cells from peripheral blood indicates a very rapid regulation of T-cell homeostasis in HIV infection...
- Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphomaAlexander Zoufaly
Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Germany
J Infect Dis 200:79-87. 2009..We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma...
- Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive diseaseJulian Schulze zur Wiesch
Infectious Disease Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
J Virol 85:1287-97. 2011..The data presented here reconcile the seemingly contradictory results of previous studies looking at Tregs in HIV and highlight the complexity of Treg-mediated immunoregulation during human viral infections...
- CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progressionJohanna Maria Eberhard
Infectious Diseases Unit, Department of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany Heinrich Pette Institute Leibniz Institute for Experimental Virology, Hamburg, Germany
PLoS ONE 9:e111323. 2014..This loss appears to be at least partially due to the distinctive vulnerability of MAIT cells to the pronounced stimulation by microbial products and cytokines during HIV-infection...
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen
Department of Internal Medicine, University of Cologne, Koln, Germany
J Antimicrob Chemother 61:914-8. 2008..The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine...
- Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virusJan van Lunzen
Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Mol Ther 15:1024-33. 2007..In conclusion, the transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus...
- Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohortMatthias Stoll
Infectious Diseases Unit, Medical University, Hanover, Germany
PLoS ONE 6:e23946. 2011..The second aim was to develop potential cost saving strategies by modelling different treatment scenarios...
- Linker-Region Modified Derivatives of the Deoxyhypusine Synthase Inhibitor CNI-1493 Suppress HIV-1 ReplicationMarcus Schröder
Institute of Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany
Arch Pharm (Weinheim) 349:91-103. 2016..By molecular dynamics simulations, the behaviour of the parent CNI-1493 in solution and its interactions with DHS were investigated. ..
- Stereoselective synthesis of D- and L-carbocyclic nucleosides by enzymatically catalyzed kinetic resolutionMiriam Mahler
Organic Chemistry, Department of Chemistry, Faculty of Sciences, University of Hamburg, Hamburg, Germany
Chemistry 18:11046-62. 2012..However, against the wild-type virus strain NL4/3, d4T was found to be more-active than D-carba-dT...
- Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional studyAlexander Zoufaly
Department of Medicine I, Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Antivir Ther 18:681-90. 2013..We aimed to identify prevalence and determinants of virological failure in HIV-infected children treated under programmatic conditions...
- How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infectionJan van Lunzen
University Medical Centre Hamburg Eppendorf, Heinrich Pette Institute for Experimental Virology and Immunology, Hamburg, Germany
Eur J Med Res 12:435-40. 2007....
- Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot StudyJan van Lunzen
Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, Hamburg, Germany ViiV Healthcare, Brentford, United Kingdom Chelsea and Westminster NHS Foundation Trust Hospital, London, United Kingdom Infectious Diseases and AIDS Units, Clinical Institute of Medicine and Dermatology, Hospital Clinic, University of Barcelona, Barcelona, Spain National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy Bristol Myers Squibb, Rueil Malmaison, France Bristol Myers Squibb, Madrid, Spain Bristol Myers Squibb, Uxbridge, United Kingdom Triple O Research Institute PA, West Palm Beach, FL Bristol Myers Squibb, Princeton, NJ Department of Infectious and Tropical Diseases, Hopital St Antoine, Assistance Publique Hopitaux de Paris, Paris, France and Institut Pierre Louis d Epidémiologie et Santé Publique, Institut National de la Sante et de la Recherche Medicale, Unité Mixte de Recherche en Santé n 1136, Paris, France
J Acquir Immune Defic Syndr 71:538-43. 2016..Adherence was lower and treatment discontinuation was higher with ATV/r+RAL. In conclusion, switching to ATV/r+RAL resulted in a higher virological rebound rate than switching to ATV/r plus tenofovir disoproxil fumarate/emtricitabine. ..
- Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen
aUniversity Medical Centre, Hamburg Eppendorf, Infectious Diseases Unit, Hamburg, Germany bNational Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy cGilead Sciences, Inc, Foster City, California, USA dHospital Universitario La Paz, IdiPAZ, Madrid, Spain eUniversity of North Carolina, Chapel Hill, North Carolina, USA fMedical University of Vienna, Vienna, Austria gUniversity of Toronto, Toronto, Ontario, Canada hHoldsworth House Medical Practice, Sydney, Australia iNew York Hospital Queens, Flushing, New York, USA
AIDS 30:251-9. 2016....
- Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infectionMalte H Wehmeyer
I, Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Martinistr, 52, Hamburg 20246, Germany
BMC Gastroenterol 14:87. 2014..There is only limited data regarding the safety and efficacy in a "real-life" cohort...
- Virological rebound and its consequences during treatment interruptionJan van Lunzen
aUniversity Medical Center Hamburg Eppendorf and Heinrich Pette Institute for Experimental Virology and Immunology, Germany bInstitute for Interdisciplinary Medicine, Hamburg, Germany
Curr Opin HIV AIDS 2:1-5. 2007..SUMMARY: Treatment interruptions cannot be recommended in HIV-infected patients outside clinical trials, especially when profound immune deficiency is found to be preexisting...
- Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)Hans Jurgen Stellbrink
Department of Medicine, Eppendorf University, Hamburg, Germany
AIDS 16:1479-87. 2002..The effect of interleukin-2 (IL-2) in combination with antiretroviral therapy on HIV-1 replication and reservoirs was investigated...